Today I posted my two-hundred-and-ninety-first YouTube Video: Quick Pick Eli Lilly (LLY)
Want to grow your portfolio and protect it too? In the toughest investing market in 40 years?
Grab my eBook, Your Best Investing Strategy for the Next 5 Years: Free download for subscribers to JubakAM.com. Just click on the image in the right margin of the JAM home page.
This week’s Quick Pick is Eli Lilly (NYSE: LLY). The worldwide explosion in diabetes has increased the demand for medicine to prevent the illness from advancing from Type 2 to Type 1 diabetes. In developing these drugs, it’s become clear these Type 2 diabetes prescriptions have also excellent potential for weight loss. Novo Nordisk’s semaglutide drug, the market leader,  has been FDA approved for both uses and is marketed as Ozempic for diabetes and Wegovy for weight loss. Eli Lilly’s competitor drug, Mounjaro, is already approved by the FDA for Type 2 diabetes. That drug is likely to be approved for weight loss as well and looks like it may work even better than Novo Nordisk’s Wegovy. illy’s second diabetes drug, Retatrutide, is still in the pipeline and just reported Phase clinical results showed a 24% loss of body weight after 11 months. Th drug  still has to go into Phase III trials but it is likely to be approved. Lilly’s stock has a 1% yield and is trading at a trailing 12 month PE of 72, so this stock is not cheap. I’ve had this stock in my Jubak Picks portfolio since November 20, 2022 and it’s up about 34% since then, but I believe we can expect another 20% to the upside with the approval of their drugs in the pipeline. The relatively low risk with a likely 20% return makes this a very attractive stock to me.
Here’s the link:
